1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Saxagliptin + dapagliflozin
Trade Name:
Qtern
Manufacturer/Distributor:
AstraZeneca
Classification:
Oral antihyperglycemic agent
DPP-4 inhibitor
Sodium-glucose contransporter 2 (SGLT2) inhibitor
ATC Class:
A10BD21 - saxagliptin and dapagliflozin
Status:
active
Notice of Compliance (yyyy/mm/dd):
2016/11/22
Date Marketed in Canada (yyyy/mm/dd):
2018/03/20
Presentation:
Tablet: 5 mg saxagliptin + 5 mg dapagliflozin. DIN: 02459175
Tablet: 5 mg saxagliptin + 10 mg dapagliflozin. DIN: 02459183
Comments:
This two component product is for use in combination with metformin as an adjunct to diet and exercise to achieve glycemic control in adults with type 2 diabetes mellitus who are inadequately controlled on metformin and saxagliptin alone, OR already controlled with metformin, saxagliptin and dapagliflozin, as individual components.
Back to:
Drug Product Listings 
